Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Mar 2023
The prevalence of diabetes and prediabetes: a population-based study.
Diabetes remains one of the top public health care priorities. Over 6% of the world's population is affected by type 2 diabetes; however, a similar number of individuals may be unaware of this diagnosis. ⋯ Our cohort study demonstrated a high prevalence of undiagnosed diabetes in the Białystok population. In addition, we showed that a large group of patients still remains undiagnosed for other hyperglycemic disorders. Abdominal obesity as well as imbalance between the fat and lean mass may predispose to diabetes.
-
Pol. Arch. Med. Wewn. · Mar 2023
Multiple drug intolerance in patients with arterial hypertension: prevalence and determining factors.
One of the reasons for poor medication compliance among patients is the occurrence of adverse drug reactions. ⋯ MDIS in patients with hypertension is common and more frequently affects women and patients with a longer known disease duration. Comorbidities increase the risk of MDIS. Its risk is strongly associated with the use of analgesics, β‑blockers, antiplatelet drugs, and antibiotics.
-
Pol. Arch. Med. Wewn. · Mar 2023
Clinical TrialAn influence of elevated heart rate by automated office blood pressure measurement on cardiovascular events risk.
The predictive value of heart rate (HR) assessed using an automated office blood pressure measurement (AOBPM) remains unknown. ⋯ High AOBPM HR is associated with a higher risk of cardiovascular events and mortality, whereas low HR may result in higher MI risk in patients with previous CVD.
-
Pol. Arch. Med. Wewn. · Mar 2023
Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies.
Despite the overall excellent efficacy of pangenotypic direct‑acting antiviral (DAA) options, there is still a small percentage of patients with hepatitis C virus (HCV) infection who do not respond to the therapy. ⋯ Our study demonstrated the excellent effectiveness of pangenotypic regimens and confirmed that most DAA nonresponders could be successfully retreated with another pangenotypic regimen. The best retreatment strategy is a triple pangenotypic regimen, especially in patients with unfavorable response factors, such as genotype 3 infection, cirrhosis, and male sex.